Ikena Oncology (NASDAQ:IMA - Get Free Report) posted its earnings results on Thursday. The company reported ($0.06) earnings per share for the quarter, topping analysts' consensus estimates of ($0.14) by $0.08, Zacks reports.
Ikena Oncology Trading Up 0.6%
NASDAQ:IMA traded up $0.09 during mid-day trading on Wednesday, reaching $15.29. The company's stock had a trading volume of 21,220 shares, compared to its average volume of 38,099. The stock has a market cap of $61.47 million, a P/E ratio of -1.99 and a beta of 0.50. The firm's fifty day moving average price is $15.82 and its two-hundred day moving average price is $15.78. Ikena Oncology has a 12-month low of $11.65 and a 12-month high of $23.28.
Wall Street Analyst Weigh In
Separately, Wedbush lowered their price objective on shares of Ikena Oncology from $25.00 to $23.00 and set a "neutral" rating on the stock in a report on Friday, July 25th.
Read Our Latest Stock Analysis on IMA
Insider Activity at Ikena Oncology
In other Ikena Oncology news, Director Otello Stampacchia purchased 267,556 shares of the company's stock in a transaction on Friday, July 25th. The stock was acquired at an average cost of $29.90 per share, for a total transaction of $7,999,924.40. Following the purchase, the director directly owned 454,982 shares of the company's stock, valued at $13,603,961.80. This trade represents a 142.75% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director David P. Bonita purchased 83,611 shares of the company's stock in a transaction on Friday, July 25th. The stock was acquired at an average price of $29.90 per share, with a total value of $2,499,968.90. Following the completion of the purchase, the director directly owned 287,885 shares in the company, valued at $8,607,761.50. This trade represents a 40.93% increase in their ownership of the stock. The disclosure for this purchase can be found here. 5.94% of the stock is currently owned by company insiders.
Institutional Trading of Ikena Oncology
An institutional investor recently raised its position in Ikena Oncology stock. Goldman Sachs Group Inc. raised its stake in Ikena Oncology, Inc. (NASDAQ:IMA - Free Report) by 62.4% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 76,464 shares of the company's stock after purchasing an additional 29,369 shares during the period. Goldman Sachs Group Inc. owned 0.16% of Ikena Oncology worth $98,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 75.00% of the company's stock.
Ikena Oncology Company Profile
(
Get Free Report)
Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.
Featured Articles
Before you consider ImageneBio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImageneBio wasn't on the list.
While ImageneBio currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access